Healthcare >> Analyst Interviews >> October 12, 2001

European Biotechnology Companies: Karl Keegan – Ubs Warburg

KARL KEEGAN graduated from University College Dublin with first-class honours degree (BSc) in pharmacology. He received a Parke-Davis Warner- Lambert scholarship to Cambridge where he attended Jesus College. Dr. Keegan specialised in biophysics, particularly the electrophysiology of neuropeptides in brain slices. He received an MPhil and PhD for this work. In 1992, he completed postdoctoral training at the Department of Neurophysiology, Division of Neuroscience, Baylor College of Medicine, Texas, funded by a National Institutes of Health scholarship and an Epilepsy Society young investigator award. In 1993, he returned to the UK to take up a research position with the Department of Biophysical Sciences at SmithKline Beecham Pharmaceuticals. While at SB, Dr. Keegan moved into a commercial and strategic role within the Strategic Product Development group, where he was responsible for marketing of the early- stage neuroscience portfolio and commercial evaluation of potential in- licensing candidates. In 1997, he joined Dresdner Kleinwort Benson as a Biotechnology Analyst, before moving to UBS Warburg in 1999. Dr. Keegan currently heads the European Biotechnology research team in London. Profile
TWST: What is your coverage area and your general expectations for these


Dr. Keegan: The coverage is everything outside of big pharma. That

includes life sciences companies,